Alternatives to Apidra If You Can't Fill Your Prescription

If your pharmacy is out of Apidra (insulin glulisine) and you need rapid-acting insulin now, the most important thing to know is this: you have options. Several other rapid-acting insulins work by the same general mechanism as Apidra, and many patients can switch with minimal disruption to their diabetes management — provided they do so under their doctor's guidance.

This guide covers the best available alternatives to Apidra, how they compare, what switching involves, and how to have the conversation with your doctor.

Why Switching Rapid-Acting Insulins Is Usually Straightforward

Apidra, Humalog, and NovoLog all belong to the same drug class: rapid-acting insulin analogs. All three start working within about 15 minutes of injection, peak within 1 hour, and last 2-4 hours. Because of these similar pharmacokinetic profiles, a 1:1 dose substitution is generally the starting point when switching between them. However, individual responses can vary, so your provider should monitor your blood glucose closely for the first 1-2 weeks after any switch.

Alternative 1: Humalog (Insulin Lispro) — Most Widely Available

Humalog (insulin lispro), made by Eli Lilly, is the most widely prescribed rapid-acting insulin in the United States. It's available in vials and several pen formats (KwikPen, Junior KwikPen, Tempo Pen), and it's on most insurance formularies as a preferred Tier 1 or Tier 2 drug. This means it's almost always easier to find at pharmacies than Apidra.

Key differences from Apidra:

Humalog is approved for children as young as 3 years old (vs. 4 years for Apidra)

Meal timing: Humalog should be injected 15 minutes before or right after a meal (Apidra allows up to 20 minutes after)

Both can be mixed with NPH insulin in the same syringe

Cash price with discount coupons: approximately $25-$35/vial (GoodRx); Lilly Insulin Value Program caps cost at $35/month

Alternative 2: NovoLog (Insulin Aspart) — Widely Stocked

NovoLog (insulin aspart), made by Novo Nordisk, is another top-tier rapid-acting insulin. It's FDA-approved for adults and children as young as 2 years old, making it the broadest-age-range rapid-acting insulin available. NovoLog is available as a vial, FlexPen, and FlexTouch, and it's widely covered by insurance plans.

Key differences from Apidra:

Meal timing: typically inject 5-10 minutes before a meal (Apidra is within 15 minutes before or 20 minutes after)

NovoLog cannot be mixed with NPH insulin in the same syringe (Apidra can)

Approved for children ≥2 years; Apidra only approved for ≥4 years

Cash price: Novo Nordisk cut NovoLog's list price by 75% in 2024; available from approximately $48-$70/vial cash price

Alternative 3: Admelog (Insulin Lispro Biosimilar) — Most Affordable Option

Admelog is a biosimilar to Humalog made by Sanofi — the same company that makes Apidra. It contains insulin lispro and is clinically equivalent to brand Humalog. Because it's a biosimilar, it's generally less expensive and may be preferred on some insurance formularies. Admelog uses the same SoloStar pen device as Apidra, which some patients find convenient when switching.

Best for: Patients who are uninsured or underinsured and looking for a lower-cost rapid-acting insulin option while Apidra is unavailable.

Alternative 4: Fiasp (Faster Insulin Aspart) — Faster Onset

Fiasp is an ultra-rapid formulation of insulin aspart made by Novo Nordisk. It has an onset approximately 5 minutes faster than standard NovoLog, making it useful for patients who eat before dosing or who struggle with postprandial spikes. However, because of its faster onset, it requires careful meal timing and isn't a straightforward 1:1 switch for all patients.

Important note: Fiasp has been in shortage itself in some U.S. markets since 2024, so verify availability before asking your doctor to switch you to this option.

Alternative 5: Lyumjev (Insulin Lispro-aabc) — Ultra-Rapid Option

Lyumjev is an ultra-rapid version of Humalog made by Eli Lilly. It contains insulin lispro-aabc — the same core insulin molecule as Humalog and Admelog, but with added excipients (treprostinil and citrate) that speed up absorption even further. It can be dosed at the start of a meal or within 20 minutes after eating, similar to Apidra's flexible timing. Patients switching from Apidra to Lyumjev may find the timing flexibility familiar.

How to Talk to Your Doctor About Switching

Before switching to any alternative, have a quick conversation with your doctor or diabetes care team. Here's what to cover:

Tell your provider why you're switching — your pharmacy doesn't have Apidra in stock

Ask whether a 1:1 dose conversion is appropriate for you, or if your doses need adjustment

Ask about any meal timing differences you should be aware of

Plan to check blood glucose more frequently in the first 1-2 weeks after switching

Remember that switching insulin is a temporary measure if Apidra is your preferred medication. Before settling on an alternative, use medfinder.com to check if Apidra is available at any pharmacies in your area. medfinder contacts pharmacies on your behalf and texts you the results, so you don't have to spend hours making calls yourself.

For more help locating Apidra before you have to switch, see: How to Find Apidra in Stock Near You (Tools + Tips).